In a new article published in The Lancet, experts review the current field of Ebola vaccine candidates and clinical trials and highlight key gaps in knowledge that need to be addressed by [Read more]
Vaccinations have begun in a first-in-human trial of an experimental Zika virus vaccine, the National Institute of Allergy and Infectious Diseases (NIAID) announced today. The experimental vaccine, known as rZIKV/D4Δ30-713, was developed [Read more]
Soligenix, Inc. announced on July 9 that it has received notice of allowance for European and Canadian patent applications further extending protection around ThermoVax® including coverage of the Company’s ricin toxin vaccine, [Read more]
The National Institute of Allergy and Infectious Diseases (NIAID) is developing a strategic framework to advance tuberculosis (TB) research and development for the next five years and beyond. The NIAID TB Strategic [Read more]
By Jacqueline K. Olive, Peter J. Hotez, Ashish Damania, Melissa S. Nolan Summary Points A social movement of public health vaccine opposition has been growing in the United States in recent years; [Read more]
Characterized by the World Health Organization as a “neglected tropical disease,” leprosy (also known as Hansen’s disease) is caused by Mycobacterium leprae. Nearly a quarter of a million people are diagnosed with [Read more]
Unprecedented levels of immunosuppression in countries like Australia and the US must be considered in planning for the risk of smallpox re-emerging in the world, an expert in infectious diseases from the [Read more]
Malaria is ranked by the Department of Defense as the number one infectious disease threat to military personnel deployed to areas where malaria is endemic. This includes countries spanning the tropical and [Read more]
The U.S. Centers for Disease Control and Prevention is seeking a vendor who can obtain anonymous pre- and post-immunization sera from specified age-groups of Europeans. The study must be conducted in a [Read more]
AbCellera Biologics Inc. this week announced that it was awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to develop rapid countermeasures against viral outbreaks. Under DARPA’s Pandemic Prevention Platform (P3) [Read more]
© 2018 STEMAR MEDIA